Lexicon Pharmaceuticals (LXRX) was given a new $6.00 price target by HC Wainwright.
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Lexicon Pharmaceuticals (LXRX) had its price target raised by Citigroup Inc. from $2.10 to $2.30. They now have a "buy" rating on the stock.
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Lexicon Pharmaceuticals (LXRX) had its price target raised by HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.